Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. The company is headquartered in Grand Cayman, the Cayman Islands.
| Revenue (TTM) | $5.00M |
| Gross Profit (TTM) | $5.00M |
| EBITDA | $-34.94M |
| Operating Margin | -330.50% |
| Return on Equity | -414.00% |
| Return on Assets | -42.20% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $-0.21 |
| Price-to-Book | 82.76 |
| Price-to-Sales (TTM) | 131.11 |
| EV/Revenue | 125.89 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 178.10% |
| Shares Outstanding | $58.73M |
| Float | $18.61M |
| % Insiders | 0.00% |
| % Institutions | 24.55% |
Volatility is currently expanding
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses.
